Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy Academic Article uri icon

Overview

MeSH Major

  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Blood Pressure
  • Hypertension
  • Hypertrophy, Left Ventricular
  • Losartan

abstract

  • Differences in blood pressure or distribution of add-on medications between treatment groups were not evident in the LIFE trial and, thus, cannot account for the observed outcome difference in the primary endpoint of risk reduction of the composite of cardiovascular death, stroke and MI favoring losartan.

publication date

  • February 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1185/030079906X162854

PubMed ID

  • 17288679

Additional Document Info

start page

  • 259

end page

  • 70

volume

  • 23

number

  • 2